TScan Therapeutics (NASDAQ:TCRX) Earns Overweight Rating from Morgan Stanley

Morgan Stanley reaffirmed their overweight rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note published on Friday morning,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other equities research analysts also recently commented on the company. Needham & Company LLC cut their price objective on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Wedbush reaffirmed an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Wednesday, March 5th. Barclays dropped their price target on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 6th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $9.33.

TScan Therapeutics Trading Down 2.8 %

Shares of TCRX stock opened at $1.74 on Friday. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock has a 50-day simple moving average of $2.28 and a 200 day simple moving average of $3.85. TScan Therapeutics has a fifty-two week low of $1.71 and a fifty-two week high of $9.69. The stock has a market capitalization of $98.47 million, a P/E ratio of -1.64 and a beta of 0.91.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.43 million. On average, sell-side analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds have recently bought and sold shares of the business. Checkpoint Capital L.P. purchased a new position in TScan Therapeutics during the 3rd quarter valued at about $4,110,000. abrdn plc grew its position in TScan Therapeutics by 137.8% during the fourth quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after purchasing an additional 512,049 shares in the last quarter. State Street Corp grew its position in TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after purchasing an additional 148,414 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock valued at $851,000 after buying an additional 145,731 shares during the period. Finally, Lynx1 Capital Management LP lifted its position in TScan Therapeutics by 2.5% in the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock worth $16,286,000 after buying an additional 132,747 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.